LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Brokerages

Shares of LivaNova PLC (NASDAQ:LIVN) have received a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $69.17.

LIVN has been the topic of several recent research reports. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday, October 4th. They issued a “buy” rating and a $65.00 price objective on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price target on shares of LivaNova in a report on Monday, November 25th. Robert W. Baird raised their price objective on LivaNova from $66.00 to $72.00 and gave the stock an “outperform” rating in a research note on Thursday, October 31st. Mizuho cut their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Finally, StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 15th.

LivaNova Stock Up 1.9 %

LIVN stock opened at $49.21 on Wednesday. The firm’s 50-day moving average is $49.44 and its two-hundred day moving average is $50.06. The company has a market capitalization of $2.67 billion, a price-to-earnings ratio of 117.17 and a beta of 1.01. LivaNova has a 52 week low of $43.15 and a 52 week high of $64.47. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Buying and Selling

In related news, Director Francesco Bianchi sold 1,250 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the transaction, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

A number of large investors have recently made changes to their positions in the stock. Canada Pension Plan Investment Board bought a new position in shares of LivaNova in the second quarter worth $88,000. Central Pacific Bank Trust Division purchased a new position in LivaNova during the third quarter worth about $178,000. Captrust Financial Advisors bought a new position in LivaNova in the 3rd quarter worth about $217,000. Sanctuary Advisors LLC bought a new position in LivaNova in the 3rd quarter worth about $219,000. Finally, Edgestream Partners L.P. purchased a new stake in shares of LivaNova in the 3rd quarter valued at about $244,000. 97.64% of the stock is owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.